



**FOR IMMEDIATE RELEASE**

**Contact:**  
Paul Byerley  
Chief Executive Officer  
+1 320.259.4321  
[pbyerley@artossinc.com](mailto:pbyerley@artossinc.com)

## **NanoBone<sup>®</sup> Bone Graft Sales Soar to New Heights Q4 Revenue Up 32% Year-Over-Year**

St. Cloud, MN, January 22, 2024 -- Artoss Inc., the exclusive distributor of NanoBone Bone Graft products throughout North America., today announced record-breaking results for the fourth quarter of 2023, with revenue surging 32% year-over-year. This exceptional performance marks a significant milestone in the company's continued growth and underscores the strong market demand for NanoBone Bone Graft.

"We are thrilled to cap off 2023 with such a remarkable quarter," said Paul Byerley, CEO of Artoss Inc. "This 32% revenue increase is a testament to the dedication and hard work of our team, as well as the unwavering trust placed in us by our customers. We are incredibly proud of the work we do, and we are confident that it is making a real difference in the lives of our customers. We look forward to continuing robust growth in 2024".

There is growing acceptance by orthopaedic surgeons that not all bone graft substitutes are the same. The rapid formation of an osteogenic matrix within 14 days and evidence of clinical and radiographic healing in as little as 8 weeks supports the use of NanoBone to treat a broad range of bone defects.

###

### **About NanoBone Bone Graft Substitute**

NanoBone was first cleared by the Food and Drug Administration (FDA) in 2015 after having been successfully used in Europe for ten years. Clinical publications have identified bone graft substitutes as an increasingly important component of many orthopaedic procedures. Consistent healing in orthopaedic procedures is a significant unmet clinical need and one where NanoBone may provide an effective option.

NanoBone is commercially available in the U.S. and is intended to fill bony voids or gaps of the skeletal system (i.e., extremities, posterolateral spine and pelvis). These osseous defects are surgically created or the result of traumatic injury to the bone and are not intrinsic to the stability of the bony structure. NanoBone SBX Putty resorbs and is replaced with bone during the healing process.

###

**About Artoss, Inc.**

Artoss, Inc. (St. Cloud, MN) is a medical device distribution company that provides the most advanced bone graft substitutes to treat multiple orthopaedic indications. The company markets NanoBone Bone Graft Substitute, which gives clinical outcomes comparable to autograft with less postoperative pain and complications. Artoss, Inc. has an experienced management team with extensive experience in orthopaedic medical devices.